What's New in Ovarian Cancer Treatment and Research: Updates from 2022 SGO Annual Meeting

Scroll down for time codes on topics covered in this video!

Want to better understand ovarian cancer, and learn the latest in ovarian cancer research, treatment, and care? Dr. Sarah Adams, gynecologic oncologist and ovarian cancer expert, joins OCRA for a conversation about what's new in the world of gynecologic cancers with a special emphasis on ovarian cancer.

In this video, Dr. Adams explains the most important updates for ovarian cancer patients and survivors, as presented at the 2022 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer. She answers attendee questions, and talks about what gives her hope for ovarian cancer progress in the future. #OCRAinConversation #ovariancancer #gynecologiconcology

According to Dr. Adams, significant progress has been made in the development of improved treatments for ovarian cancers as well as other gynecologic cancers. There is a strong focus on strategies to overcome treatment resistance, and promising new drugs on the horizon, including drugs that appear to be effective in platinum resistant tumors. It is critical that the field address disparities in treatment and access to treatment, and also to maintain a focus on quality of life and symptom control for those in treatment for gynecologic cancers.

Dr. Adams is Associate Professor in the Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, and Associate Director of Translational Research at the University of New Mexico.

OCRA's webinar series is supported by GSK, Merck, and AstraZeneca.

Timecodes
0:00 - Introduction
4:28 – Has There Been Progress in Ovarian Cancer Research?
8:21 – COVID’s Effects on Ovarian Cancer Research and Care
11:28 – Ovarian Cancer Standard of Treatment Updates
11:54 – IV Chemotherapy vs IP Chemotherapy, plus Bevacizumab (Avastin) with Weekly Taxol
13:25 – Extending Survival with Front Line Treatments
14:31 – IP Carboplatin vs IP Chemotherapy without Taxol
16:14 – PARP Inhibitors for Maintenance Therapy
17:49 – Genetic Testing for Better Ovarian Cancer Treatment
18:19 – Treatment Options for Recurrent Ovarian Cancer
20:13 – Resistance to Ovarian Cancer Treatment
21:05 – PARP Inhibitors After Chemotherapy
22:15 – Overcoming Bevacizumab (Avastin) Resistance with Glutaminase Inhibitors
24:30 – Targeted Therapies and Biomarkers to Combat Platinum Resistance
25:56 – PARP Inhibitors as Frontline Neoadjuvant Therapy
28:32 – Immunotherapy and Ovarian Cancer
29:11 – Clear Cell Ovarian Cancer and Immunotherapy
30:50 – Immunotherapy, PARP Inhibitors, and Genetic Markers
33:12 – Antibody Drug Conjugates to Fight Ovarian Tumor Cells
37:24 – Synthetic Proteins in Combination with Pembrolizumab (Keytruda) for Platinum Resistance
39:08 – Artificial Intelligence and Ovarian Cancer
40:13 – Racial and Financial Disparities in Ovarian Cancer
45:46 – Improving Quality of Life
46:58 – Nutrition and Ovarian Cancer
48:28 – Managing Peripheral Neuropathy from Cancer Treatment
50:02 – Study on Ketogenic Diet and Tumor Growth
51:48 – Question and Answer Begins
52:14 – Are PARP Inhibitors Effective Without BRCA Mutations?
54:28 – How Long Should A Patient Stay on PARP Inhibitors?
55:44 – If a PARP Inhibitor Doesn’t Work Should I Try Another?
56:54 – What Are Genetic and Genomic Testing, and Should I Get Them Done Twice?
59:59 – How Can I Prevent Ovarian Cancer Recurrence?
1:01:37 – Is There a Relationship Between Hormone Replacement Therapy (HRT) and Ovarian Cancer?
1:02:59 – Does Ovarian Cancer Start in the Fallopian Tubes?
1:04:16 – Should I Participate in a Clinical Trial?

• Category

  Ovarian, Fallopian Tube, and Peritoneal Cancer